tirzepatide vs semaglutide comparison efficacy side effects Cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice Subcutaneously administered tirzepatide vs semaglutide
Description
Kerem Bortecen
The primary endpoint (a composite of cardiovascular death or heart failure hospitalization) was significantly reduced: 9.9% of tirzepatide patients vs 15.3% of placebo patients had an event
Its thought that people with more body mass or a higher BMI may have a higher basal metabolic rate because their bodies require more energy to sustain and maintain physiological functioning
This dosing is based on clinical trials and FDA guidelines to maximize antiviral effect while minimizing side effects
[CrossRef] [PubMed] [Google Scholar] Insulin receptor substrate proteins and diabetes
